| abstract |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine, namely to arthrology, rheumatology, and can be used for treating rheumatoid arthritis. That is ensured by introducing human CD20 specific small modular immune-pharmaceutical (SMIP) protein in a therapeutically effective amount to the patient. The introduction is single, and the supporting treatment is not performed for approximately three months to two years after the introduction of a first single dose. ^ EFFECT: single introduction provides almost complete B-cell elimination and considerable prolonged rheumatoid factor level reduction in said category of patients. ^ 24 cl, 4 tbl, 8 ex, 5 dwg |